Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 21.0
(0.92%)
CNY 21.0
(0.92%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -782.72 Million | -719.17 Million | -422.4 Million | -514.98 Million | -354.35 Million | -155.51 Million |
| Net Income | -1.05 Billion | -958.12 Million | -772.69 Million | -643.62 Million | -928.93 Million | -237.83 Million |
| Depreciation & Amortization | 104.31 Million | 89.29 Million | 80.46 Million | 56.39 Million | 42.56 Million | 21.87 Million |
| Deferred income taxes | 15.84 Million | 1.81 | -6.56 Million | -11.86 Million | -484.81 Thousand | 55.07 Million |
| Stock-based compensation | 118.2 Million | 152.33 Million | 185.77 Million | 79.32 Million | 636.62 Million | 404.65 Thousand |
| Change in working capital | 20.82 Million | -19.1 Million | 77.59 Million | -2.26 Million | -107.79 Million | 4.51 Million |
| Other non-cash items | 16.89 Million | 16.43 Million | 13.03 Million | 7.05 Million | 3.66 Million | 456.5 Thousand |
| Investing Cash Flow | -509.62 Million | -602.8 Million | 12.83 Million | -357.22 Million | -183.88 Million | -290.06 Million |
| Investments in PPE | -499.91 Million | -544.95 Million | -217.5 Million | -130.61 Million | -185.18 Million | -224.62 Million |
| Acquisitions | -24 Million | 5554.84 | 0.06 | -54.17 Thousand | 3.07 Million | -71.49 Million |
| Investment purchases | -482.42 Million | -940 Million | -278.95 Million | -1.03 Billion | -28.25 Million | -5 Million |
| Sales/Maturities of investments | 496.71 Million | 882.15 Million | 509.29 Million | 808.24 Million | 6.47 Million | 20.41 Million |
| Other Investing Activities | 3608.74 | 0.88 | 230.34 Million | 0.02 | 20 Million | -9.36 Million |
| Financing Cash Flow | 444.93 Million | 3.71 Billion | 198.94 Million | 1.15 Billion | 539.75 Million | 418.8 Million |
| Debt repayment | -100 Million | -10.82 Million | -50.04 Million | -114.04 Million | - | - |
| Dividends payments | -34.09 Million | -13.12 Million | -788.92 Thousand | -1.03 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -26.26 Million | 3.73 Billion | 249.77 Million | 1.27 Billion | 539.75 Million | 418.8 Million |
| Accounts receivables | -42.88 Million | 15.2 Million | -24 Million | -12.71 Million | -100.64 Million | 41.53 Million |
| Accounts payables | 149.89 Million | 6.57 Million | 109.33 Million | 20.39 Million | 12.83 Million | -30.97 Million |
| Inventory | -86.18 Million | -40.88 Million | -7.72 Million | -9.93 Million | -19.97 Million | -6.04 Million |
| Other working capital | -0.36 | 0.83 | -1.01 | -0.04 | -82.80 | 10.55 Million |
| Cash at beginning of period | 2.48 Billion | 93.54 Million | 305.17 Million | 23.92 Million | 22.33 Million | 49.09 Million |
| Cash at end of period | 1.64 Billion | 2.48 Billion | 93.54 Million | 305.17 Million | 23.92 Million | 22.33 Million |
| Capital Expenditure | -499.91 Million | -544.95 Million | -217.5 Million | -130.61 Million | -185.18 Million | -224.62 Million |
| Effect of forex changes on cash | 1.4 Million | 2.26 Million | -1 Million | -1.72 Million | 82.87 Thousand | 7738.62 |
| Net cash flow / Change in cash | -846.01 Million | 2.39 Billion | -211.63 Million | 281.24 Million | 1.59 Million | -26.76 Million |
| Free Cash Flow | -1.28 Billion | -1.26 Billion | -639.91 Million | -645.6 Million | -539.53 Million | -380.13 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -249.1 Million | -239.32 Million | -205.65 Million | -380.14 Million | -1.05 Billion | -259.76 Million |
| Depreciation & Amortization | - | 35.03 Million | 35.03 Million | 30.48 Million | 104.31 Million | -38.24 Million |
| Deferred income taxes | - | - | - | -107.34 Million | 15.84 Million | 86.78 Million |
| Stock-based compensation | - | 28.66 Million | - | 118.2 Million | 118.2 Million | -53.49 Million |
| Change in working capital | - | 19.32 Million | - | -10.86 Million | 20.82 Million | 4.68 Million |
| Other non-cash items | 43.07 Million | 144.92 Million | -124.93 Million | 129.39 Million | 16.89 Million | 18.92 Million |
| Investing Cash Flow | -61.84 Million | 32.3 Million | -175.78 Million | -57.91 Million | -509.62 Million | -73.63 Million |
| Investments in PPE | -58.7 Million | -68.8 Million | -98.95 Million | -38.09 Million | -499.91 Million | -80.45 Million |
| Acquisitions | -5.86 Million | - | -2 Million | -23.99 Million | -24 Million | -6.82 Million |
| Investment purchases | -70.29 Million | -38.05 Million | -182.55 Million | -211.7 Million | -482.42 Million | -45.71 Million |
| Sales/Maturities of investments | 73.02 Million | 139.16 Million | 107.71 Million | 215.87 Million | 496.71 Million | 52.53 Million |
| Other Investing Activities | - | 102.7 Million | -74.83 Million | -0.68 | 3608.74 | 6.82 Million |
| Financing Cash Flow | 130.48 Million | 112.21 Million | 584.44 Million | 116.43 Million | 444.93 Million | 35.29 Million |
| Debt repayment | -154.84 Million | -131.19 Million | -610.16 Million | -50 Million | -100 Million | -48.61 Million |
| Dividends payments | - | -15.3 Million | -14.91 Million | -9.77 Million | -34.09 Million | -9.25 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -24.36 Million | -1.61 Million | -10.8 Million | 2.21 Million | -26.26 Million | 93.15 Million |
| Accounts receivables | - | 11.95 Million | - | -42.88 Million | -42.88 Million | -51.06 Million |
| Accounts payables | - | - | - | - | 149.89 Million | 53.49 Million |
| Inventory | - | -21.3 Million | - | -86.18 Million | -86.18 Million | 55.74 Million |
| Other working capital | - | 28.66 Million | - | 118.2 Million | -0.36 | -53.49 Million |
| Cash at beginning of period | 1.69 Billion | 1.72 Billion | 1.64 Billion | 1.8 Billion | 2.48 Billion | 2.08 Billion |
| Cash at end of period | 1.56 Billion | 1.69 Billion | 1.72 Billion | 1.64 Billion | 1.64 Billion | 1.8 Billion |
| Capital Expenditure | -58.7 Million | -68.8 Million | -98.95 Million | -38.09 Million | -499.91 Million | -80.45 Million |
| Effect of forex changes on cash | - | 211.25 Thousand | 13.97 Thousand | -4.06 Million | 1.4 Million | 3.48 Million |
| Net cash flow / Change in cash | -131.02 Million | -26.96 Million | 78.06 Million | -165.81 Million | -846.01 Million | -275.97 Million |
| Free Cash Flow | -264.73 Million | -198.24 Million | -429.54 Million | -258.36 Million | -1.28 Billion | -321.56 Million |
8961
603976
CLIS
6284
8750
HPIFY